Payment overview · 2025
General Payments
$755.72
30 reported records · 10 companies
Healthcare provider profile · identity verified
Hongsheng Wei, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ARCADIA, CA · NPI 1689694580
Verified facts
What the public records show
CMS Open Payments records show Hongsheng Wei, MD received $755.72 in general payments during 2025 across 30 reported records.
ABBVIE INC. accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $227.92 | 30.2% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $161.05 | 21.3% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $96.10 | 12.7% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $87.70 | 11.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.03 | 6.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.19 | 5.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.70 | 3.7% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.13 | 3.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.50 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.40 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $755.72 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $227.92 | 8 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $227.92 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $110.70 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $96.10 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $96.10 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $87.70 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $50.35 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $45.03 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.19 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 182 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 196 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 207 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 86 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 22 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
182 | 45 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
86 | 26 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
196 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
207 | 40 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
207 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
146 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1248 | 319 |
| Amlodipine Besylate | Amlodipine Besylate | 1077 | 244 |
| Metformin Hcl | Metformin Hcl | 514 | 107 |
| Losartan Potassium | Losartan Potassium | 496 | 120 |
| Clopidogrel | Clopidogrel Bisulfate | 492 | 104 |
| Zolpidem Tartrate | Zolpidem Tartrate | 460 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 454 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 397 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 333 | 85 |
| Vascepa | Icosapent Ethyl | 318 | 74 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 281 | 58 |
| Lorazepam | Lorazepam | 256 | 59 |
| Donepezil Hcl | Donepezil Hcl | 227 | 53 |
| Glipizide | Glipizide | 212 | 45 |
| Jardiance | Empagliflozin | 207 | 40 |
| Ezetimibe | Ezetimibe | 199 | 49 |
| Farxiga | Dapagliflozin Propanediol | 196 | 33 |
| Icosapent Ethyl | Icosapent Ethyl | 191 | 70 |
| Mirtazapine | Mirtazapine | 190 | 45 |
| Famotidine | Famotidine | 184 | 60 |
| Creon | Lipase/Protease/Amylase | 182 | 45 |
| Januvia | Sitagliptin Phosphate | 181 | 34 |
| Montelukast Sodium | Montelukast Sodium | 179 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 43 |
| Atenolol | Atenolol | 146 | 37 |
| Eliquis | Apixaban | 146 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 142 | 77 |
| Memantine Hcl Er | Memantine Hcl | 137 | 33 |
| Azithromycin | Azithromycin | 136 | 112 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 133 | 92 |
| Carvedilol | Carvedilol | 132 | 27 |
| Gabapentin | Gabapentin | 130 | 47 |
| Omeprazole | Omeprazole | 127 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 39 |
| Xarelto | Rivaroxaban | 120 | 21 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 116 | 37 |
| Folic Acid | Folic Acid | 111 | 40 |
| Nifedipine Er | Nifedipine | 109 | 25 |
| Allopurinol | Allopurinol | 103 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 99 | 18 |
| Levofloxacin | Levofloxacin | 99 | 86 |
| Diclofenac Sodium | Diclofenac Sodium | 98 | 46 |
| Finasteride | Finasteride | 95 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 91 | 21 |
| Memantine Hcl | Memantine Hcl | 91 | 21 |
| Glimepiride | Glimepiride | 88 | 19 |
| Alendronate Sodium | Alendronate Sodium | 87 | 26 |
| Linzess | Linaclotide | 86 | 26 |
| Telmisartan | Telmisartan | 84 | 26 |
| Temazepam | Temazepam | 84 | 12 |
| Nitroglycerin | Nitroglycerin | 80 | 58 |
| Amoxicillin | Amoxicillin | 78 | 60 |
| Fenofibrate | Fenofibrate Nanocrystallized | 78 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 76 | 33 |
| Metformin Hcl Er | Metformin Hcl | 75 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 19 |
| Rybelsus | Semaglutide | 69 | suppressed |
| Cyclosporine | Cyclosporine | 67 | 28 |
| Ketoconazole | Ketoconazole | 67 | 36 |
| Simvastatin | Simvastatin | 66 | 19 |
| Lisinopril | Lisinopril | 62 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 17 |
| Ranolazine Er | Ranolazine | 62 | 16 |
| Hydrocortisone | Hydrocortisone | 60 | 25 |
| Celecoxib | Celecoxib | 59 | 29 |
| Restasis | Cyclosporine | 58 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 54 | 21 |
| Bethanechol Chloride | Bethanechol Chloride | 54 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 12 |
| Latanoprost | Latanoprost | 54 | 13 |
| Aripiprazole | Aripiprazole | 53 | suppressed |
| Meloxicam | Meloxicam | 51 | 18 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 50 | 21 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 50 | 11 |
| Valsartan | Valsartan | 50 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 14 |
| Repaglinide | Repaglinide | 49 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 22 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 48 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 16 |
| Gemfibrozil | Gemfibrozil | 45 | suppressed |
| Eszopiclone | Eszopiclone | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 12 |
| Tradjenta | Linagliptin | 42 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 41 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | suppressed |
| Alprazolam | Alprazolam | 39 | 11 |
| Entecavir | Entecavir | 38 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | 20 |
| Zenpep | Lipase/Protease/Amylase | 36 | 13 |
| Clonidine Hcl | Clonidine Hcl | 35 | 15 |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 26 |
| Furosemide | Furosemide | 32 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Prednisone | Prednisone | 32 | 27 |
| Ciclopirox | Ciclopirox Olamine | 31 | 13 |
| Dutasteride | Dutasteride | 31 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 31 | 19 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 15 |
| Pentoxifylline | Pentoxifylline | 26 | 11 |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 21 |
| Ciclopirox | Ciclopirox | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Colchicine | Colchicine | 25 | 14 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 24 | 22 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 24 | 23 |
| Livalo | Pitavastatin Calcium | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Ursodiol | Ursodiol | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Erythromycin | Erythromycin Base | 19 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 19 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 18 |
| Prolia | Denosumab | 18 | 11 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 15 | 15 |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Lyrica | Pregabalin | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Acyclovir | Acyclovir | 12 | 11 |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Orencia | Abatacept | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $755.72 · 30 records | ABBVIE INC. | BREZTRI, CREON, FARXIGA, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, OTEZLA, PAXLOVID, REPATHA, TRELEGY ELLIPTA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error